Microbot Medical LIBERTY: What The Robotic System Does

What Is Microbot Medical's LIBERTY System?

LIBERTY is an endovascular robotic system built by Microbot Medical Inc., a commercial-stage medical device company. It lets a physician remotely deliver and manipulate guidewires and catheters during peripheral endovascular procedures from a control console, rather than standing at the patient's side.

The company describes LIBERTY as the first single-use, fully disposable robotic system of its kind to receive FDA clearance for this use. Because the robotic unit itself is single-use rather than a large capital piece of equipment that must be purchased, installed, and maintained, Microbot Medical positions it as a lower-infrastructure alternative to older robotic platforms, and states it can be set up in under five minutes.

This page summarizes publicly reported facts about LIBERTY's design, clearance, and rollout. It does not evaluate clinical efficacy beyond what is stated in the company's disclosed trial results, and nothing here is medical or investment advice.

FDA Clearance And Clinical Data

The U.S. FDA granted 510(k) clearance for the LIBERTY Endovascular Robotic System on September 8, 2025, for use in peripheral endovascular procedures. A 510(k) clearance means the FDA determined the device is substantially equivalent to a legally marketed predicate device; it is a distinct regulatory pathway from full premarket approval, and it does not itself constitute a claim of superiority over other tools.

Microbot Medical has reported that its pivotal clinical study showed 100% technical success in robotic navigation to the target and zero device-related adverse events, along with a 92% relative reduction in physician radiation exposure compared with manual technique. These are the company's own reported results as disclosed in its press materials and regulatory filings; readers evaluating clinical performance should consult the underlying study data and independent literature rather than treat marketing summaries as a substitute.

As with any newly cleared device, real-world outcomes at scale, across more operators and case types, will take time to accumulate independent of the pivotal trial data.

Commercial Rollout And Hospital Adoption

Following clearance, Microbot Medical has been rolling out LIBERTY to hospitals and health systems, reporting adoptions at academic medical centers in markets including New York City, Boston, and, more recently, Pennsylvania, as it expands presence in the Northeast United States.

The company has also presented LIBERTY at industry venues such as the Society of Robotic Surgery annual meeting and investor conferences, and has reported recognition including an Innovative Start-Up Award from Surgical Robotics Technology. These are company-reported milestones tracking commercial and industry visibility, not independent verification of clinical outcomes.

How LIBERTY Fits Among Surgical And Medical Robots

LIBERTY sits within the broader category of robot-assisted procedure systems that our site tracks under surgical robots. Unlike large fixed-console platforms, LIBERTY's single-use, disposable design is a different commercialization model than the capital-equipment approach used by more established systems such as the da Vinci Surgical System.

For background on how robotic assistance is used across hospitals more broadly, see our robotics in healthcare overview and our medical robot companies roundup, which tracks makers across surgical, delivery, and care-support robotics.

Company Background: Microbot Medical Inc.

Microbot Medical Inc. trades on Nasdaq under the ticker MBOT and operates with US and Israel-based teams. Harel Gadot serves as the company's CEO, President, and Chairman. The company describes itself as a commercial-stage medical device company focused on transforming endovascular procedures through robotics.

Because MBOT is a publicly traded company, search interest in "Microbot Medical" often mixes company and stock-related queries with technology questions. This page covers the LIBERTY system and its regulatory status only; it does not offer investment guidance, price targets, or trading recommendations. Readers researching MBOT as an investment should consult the company's SEC filings and a licensed financial advisor.